Chimeric antigen receptor-based cellular therapy for T-cell malignancies.

Area of Science:

• Immunology
• Synthetic Biology
• Oncology

Background:

• Chimeric antigen receptor (CAR) T-cell therapy, using single-chain variable fragments (scFvs) to target tumor antigens, is effective for B-lineage hematologic malignancies.
• Treatment for relapsed or refractory (R/R) T-cell malignancies remains suboptimal due to challenges like antigen sharing and T-cell aplasia.

Purpose of the Study:

• This review explores CAR-based cellular therapies for T-cell malignancies.
• It discusses various immune effector cells (IECs) and strategies to improve CAR T-cell therapy outcomes.

Main Methods:

• Review of current literature on CAR T-cell therapy for T-cell malignancies.
• Exploration of different immune effector cells (IECs) including T cells, NK cells, NKT cells, CIK cells, and γδ T cells.
• Discussion of multi-antigen targeting and emerging technologies.

Main Results:

• CAR T-cell therapy faces significant hurdles in treating T-cell malignancies, including fratricide and increased risk of relapse.
• Severe T-cell aplasia post-infusion further compromises immunocompromised patients.

Conclusions:

• Novel CAR-based strategies, including diverse immune effector cells and multi-antigen targeting, are crucial for improving outcomes in T-cell malignancies.
• Ongoing research and clinical trials aim to overcome current limitations in CAR T-cell therapy for these cancers.